Syros Pharmaceuticals, Inc. (SYRS) by event type
SYRS moves most on analyst downgrades — a median of -4.00% at 30 minutes across 14 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the SYRS overview →
How SYRS reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades 2,574 of 2,603 | 14 | -4.00% | 29% | -7.96% |
| Coverage initiations 1,400 of 2,283 | 24 | -0.04% | 46% | +1.40% |
| Rating reiterations 3,236 of 3,522 | 21 | -0.39% | 43% | -1.56% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 2 further classes were observed with fewer than 10 measured events and are not published.
That’s how SYRS usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst downgrades → · Coverage initiations → · Rating reiterations → · SYRS overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | 309 | 0.00% | 50% |
| MENLO THERAPEUTICS INC COMMON (MNLO) | 308 | 0.00% | 49% |
| Adverum Biotechnologies, Inc. (ADVM) | 306 | 0.00% | 49% |
| Establishment Labs Holdings Inc. - Common Shares (ESTA) | 306 | +0.13% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.